Oncolytics Biotech (TSE:ONC) Hits New 12-Month Low – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC) hit a new 52-week low on Monday . The company traded as low as C$0.98 and last traded at C$1.00, with a volume of 139671 shares. The stock had previously closed at C$1.07.

Wall Street Analysts Forecast Growth

Separately, Raymond James raised Oncolytics Biotech to a “moderate buy” rating in a research note on Thursday, November 14th.

Oncolytics Biotech Trading Up 2.9 %

The stock has a market capitalization of C$80.70 million, a PE ratio of -2.76 and a beta of 1.35. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The firm has a 50 day moving average price of C$1.23 and a 200 day moving average price of C$1.36.

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings data on Tuesday, November 12th. The company reported C($0.12) earnings per share for the quarter, missing the consensus estimate of C($0.11) by C($0.01). During the same period last year, the firm earned ($0.14) earnings per share. Equities analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.